Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome

your_photo/iStock via Getty Images I covered Stoke Therapeutics (NASDAQ:STOK) thrice in the last few years. If you read those articles, you will see I have held divergent views about this company over the years. First, I held the view that STOK was overvalued when it had a market cap of $1.88bn - the stock is down 73% since then; then, 3 years later, I thought it was undervalued when it had a market cap of$ 364mn, and the stock is up 64% since then; but in my last article, after it produced unsatisfactory d ...